Osteocalcin, a small bone-specific protein that influences bone formation, may facilitate the development of drugs to combat bone-related diseases, such as osteoporosis and bone metastases of cancer, say McMaster University researchers. Their study is to be published in the October 30 issue of Nature, a high-impact scientific journal.
Although it’s generally accepted that osteocalcin, discovered in 1976, binds to the mineral component of bone, called hydroxyapatite, the biological function and the 3-D structure of the protein have never been known. Now McMaster researchers have unlocked the mystery.
Osteocalcin is used as a biological marker for assessing bone disease and is closely linked to bone turnover, a fine balance between bone resorption and formation which goes on constantly during life.
Veronica McGuire | McMaster University
New malaria analysis method reveals disease severity in minutes
14.08.2017 | University of British Columbia
New type of blood cells work as indicators of autoimmunity
14.08.2017 | Instituto de Medicina Molecular
16.08.2017 | Event News
04.08.2017 | Event News
26.07.2017 | Event News
18.08.2017 | Life Sciences
18.08.2017 | Physics and Astronomy
18.08.2017 | Materials Sciences